BBIO insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 475686 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $79.04 to $79.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. | 2026-11-19 | 2026-11-20 | ≈ $118,939.50 1,500 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 477186 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $78.00 to $78.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. | 2026-11-19 | 2026-11-20 | ≈ $665,977.55 8,500 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 485686 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. | 2026-11-18 | 2026-11-20 | ≈ $678,884.05 8,723 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 494409 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. | 2026-11-18 | 2026-11-20 | ≈ $98,318.15 1,277 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 243327 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. | 2026-11-18 | 2026-11-20 | ≈ $2,372,948.28 30,490 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 273817 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. | 2026-11-18 | 2026-11-20 | ≈ $345,692.28 4,490 shares/units | SEC 4 | Follow |
| Trimarchi Thomas President and CFO · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 313748 · Securities delivered or withheld for tax or exercise payment · Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 41,193 shares of Common Stock underlying the Reporting Person's RSUs. | 2026-11-16 | 2026-11-18 | 22,781 shares/units | SEC 4 | Follow |
| Apuli Maricel Chief Accounting Officer · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 115973 · Securities delivered or withheld for tax or exercise payment · Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 9,261 shares of Common Stock underlying the Reporting Person's RSUs. | 2026-11-16 | 2026-11-18 | 4,714 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 84755 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. · The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. | 2026-11-16 | 2026-11-18 | 6,519 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 103984 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. · The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. | 2026-11-16 | 2026-11-18 | 11,554 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 97997 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. · The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. | 2026-11-16 | 2026-11-18 | 19,599 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Exercise or conversionFiling detailsSEC transaction code M Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 33544 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. · The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. | 2026-11-16 | 2026-11-18 | 33,544 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Other transactionFiling detailsSEC transaction code F Common Stock · Direct ownership · Reported balance after transaction: 278307 · Securities delivered or withheld for tax or exercise payment · Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,216 shares of Common Stock underlying the Reporting Person's RSUs. | 2026-11-16 | 2026-11-18 | 36,236 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 314543 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. | 2026-11-16 | 2026-11-18 | 6,519 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 308024 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. | 2026-11-16 | 2026-11-18 | 11,554 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 296470 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. | 2026-11-16 | 2026-11-18 | 19,599 shares/units | SEC 4 | Follow |
| Kumar Neil Chief Executive Officer · Director · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 276871 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. | 2026-11-16 | 2026-11-18 | 33,544 shares/units | SEC 4 | Follow |
| Apuli Maricel Chief Accounting Officer · BridgeBio Pharma, Inc. | BBIO BridgeBio Pharma, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 120687 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on September 8, 2025. | 2026-10-30 | 2026-11-03 | ≈ $145,700.00 2,000 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.